Commercialization
Intelligence for Cell & Gene Therapies.
Identify commercialization risk years before launch using real-world CGT failure intelligence. Benchmark, simulate, and de-risk your therapy with Negative Knowledge.
Six intelligence layers.
One commercialization verdict.
A structured library of failed CGT launches, FDA holds, reimbursement collapses, and manufacturing breakdowns.
Match your therapy against historical analogs. Receive % similarity to Zynteglo, Skysona, MB-207 and more.
Weighted scoring across Mfg, Reimbursement, Sites, Demand, Safety, and Operations updated in real time.
Modify price, throughput, treatment centers, vein-to-vein time — watch your readiness curve respond live.
Detect commercialization fragility patterns 18–36 months before launch decisions become irreversible.
Distinct benchmark ranges for AAV, Lentiviral, CAR-T, NK, Stem Cell, CRISPR and mRNA programs.
Negative Knowledge is the most underused asset in biotech.
Glybera withdrew at $1M with 31 patients treated. Zynteglo exited the EU before reimbursement. Skysona retired post-launch. CRI quantifies the patterns these programs shared — and how close your therapy sits to them.
Run a CRI simulation in under 4 minutes.
Load a demo CAR-T, AAV, or rare disease gene therapy — or input your own program — and receive a board-ready commercialization risk assessment with analog comparisons and prioritized recommendations.